Phase I and pharmacokinetic study of D-verapamil and doxorubicin
Authors:
- P MeredithPMP Meredith
- U TraugottUTU Traugott
Open Access
- 1 December 1991
- journal article
- clinical trial
- Published by Springer Nature in British Journal of Cancer
- Vol. 64 (6) , 1168-1171
Abstract
The calcium antagonist verapamil (a mixture of D- and L-racemers) is a potent modulator of the multi-drug resistance phenotype in vitro at a concentration of 6 microM. Clinical studies have shown dose-limiting toxicity of hypotension and heart block when plasma levels approach the concentrations active in vitro. Previous data indicate that the D-isomer is less cardioactive than the L-isomer but they appear to be equipotent in reversing drug resistance in vitro. In an attempt to increase plasma verapamil concentrations, we have treated ten patients (total of 27 courses) with oral D-verapamil (DVPM), 150-300 mg 6 h, and doxorubicin i.v. 70 mg m2 q 3 weeks. Hypotension (supine systolic BP less than 100 mmHg or a fall in systolic BP of greater than 30 mmHg) occurred in 5/6 patients at 1200 mg day DVPM, in 1/5 at 800 mg day, and in 1/5 at 600 mg day. PQ prolongation (greater than 0.23 s) was demonstrated in 2/5 patients at 800 mg day DVPM. Plasma levels of DVPM and its active metabolite norverapamil were measured and, combining these, levels of 3-4 microM were achieved at 1200 mg day DVPM; however this dose is likely to lead to unacceptable toxicity in the outpatient setting. Using an oral outpatient schedule of administration, an appropriate dose of DVPM is 800 mg day. This provides a combined plasma level (for VPM and DVPM) of 2-3 microM. If DVPM is to prove useful as a resistance modulator, it may require to be administered intravenously with careful inpatient monitoring and support.Keywords
This publication has 16 references indexed in Scilit:
- The activity of verapamil as a resistance modifier in vitro in drug resistant human tumour cell lines is not stereospecificBiochemical Pharmacology, 1990
- Inherent adriamycin resistance in a murine tumour line: circumvention with verapamil and norverapamilBritish Journal of Cancer, 1989
- Expression of Multidrug Resistance Gene in Human CancersJNCI: Journal of the National Cancer Institute, 1989
- Effect of verapamil on doxorubicin activity and pharmacokinetics in mice bearing resistant and sensitive solid tumorsCancer Chemotherapy and Pharmacology, 1988
- Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients.Journal of Clinical Oncology, 1987
- The effect of verapamil on the pharmacokinetics of adriamycinCancer Chemotherapy and Pharmacology, 1986
- Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cellsCell, 1986
- The effect of dextro-, levo-, and racemic verapamil on atrioventricular conduction in humansAmerican Heart Journal, 1985
- Stereoselective first‐pass metabolism of highly cleared drugs: studies of the bioavailability of L‐ and D‐verapamil examined with a stable isotope technique.British Journal of Clinical Pharmacology, 1984
- Rapid high-performance liquid chromatographic method for the measurement of verapamil and norverapamil in blood plasma or serumJournal of Chromatography A, 1981